Ocugen, Inc. (NASDAQ:OCGN) to Post FY2025 Earnings of ($0.27) Per Share, Chardan Capital Forecasts

Ocugen, Inc. (NASDAQ:OCGN) – Research analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Ocugen in a research note issued to investors on Wednesday, May 15th. Chardan Capital analyst D. Gataulin anticipates that the company will earn ($0.27) per share for the year. Chardan Capital has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.29) per share.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $1.01 million during the quarter. During the same quarter in the prior year, the company posted ($0.07) earnings per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Ocugen in a research report on Wednesday.

Ocugen Trading Down 0.3 %

NASDAQ OCGN traded down $0.01 during mid-day trading on Friday, reaching $1.98. 1,330,784 shares of the stock were exchanged, compared to its average volume of 7,967,821. The stock has a market cap of $508.23 million, a P/E ratio of -7.92 and a beta of 3.49. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.87 and a quick ratio of 2.51. Ocugen has a one year low of $0.35 and a one year high of $2.11. The stock has a 50 day simple moving average of $1.47 and a 200-day simple moving average of $0.87.

Institutional Trading of Ocugen

Several hedge funds have recently bought and sold shares of OCGN. Tidal Investments LLC bought a new position in shares of Ocugen in the first quarter valued at $108,000. State Board of Administration of Florida Retirement System bought a new position in Ocugen in the 1st quarter valued at about $132,000. Headlands Technologies LLC acquired a new position in Ocugen during the 1st quarter valued at about $66,000. David J Yvars Group bought a new stake in Ocugen during the 1st quarter worth approximately $35,000. Finally, Truefg LLC purchased a new stake in shares of Ocugen in the first quarter worth approximately $34,000. Institutional investors and hedge funds own 10.27% of the company’s stock.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.